Chronic kidney disease mineral bone disorder (MBD) belongs to the bone disease pathology, is characterized by "inadequate bone mineralization" (bonemineralizationdeficiency), which is associated with chronic kidney disease of electrolyte and the direct result of endocrine disorder.
This report contains market size and forecasts of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) in global, including the following market information:
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) companies in 2021 (%)
The global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Control Hyperphosphatemia Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) include Akebia, Astellas, Takeda, Vifor, Abbvie, Fresenius, Abbott, Novadiol and Japan Tobacco Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Segment Percentages, by Type, 2021 (%)
Control Hyperphosphatemia
Maintain Blood Calcium Levels
Control PTH Level
Correct Acidosis
Other
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores 
Other
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) revenues share in global market, 2021 (%)
Key companies Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) sales in global market, 2017-2022 (Estimated), (MT)
Key companies Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Akebia
Astellas
Takeda
Vifor
Abbvie
Fresenius
Abbott
Novadiol
Japan Tobacco Company
Daiichi-Sankyo
Shield
Spectrum
OPKO
Ardelyx
Sanofi Genzyme
Amgen